Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.38 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.29 | |||||
Beneish M-Score | 21.93 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | 50.3 | |||||
3-Year EPS without NRI Growth Rate | 44.7 | |||||
3-Year Book Growth Rate | 9.1 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.83 | |||||
9-Day RSI | 56.35 | |||||
14-Day RSI | 52.61 | |||||
6-1 Month Momentum % | 33.04 | |||||
12-1 Month Momentum % | 9.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.96 | |||||
Quick Ratio | 4.96 | |||||
Cash Ratio | 3.58 | |||||
Days Sales Outstanding | 40.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | -5.03 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 48.8 | |||||
Net Margin % | 52.93 | |||||
FCF Margin % | 29.86 | |||||
ROE % | 74.55 | |||||
ROA % | 45.41 | |||||
ROIC % | 143.38 | |||||
ROC (Joel Greenblatt) % | 315.18 | |||||
ROCE % | 51.14 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 2.78 | |||||
PE Ratio without NRI | 2.78 | |||||
Price-to-Owner-Earnings | 6.76 | |||||
PS Ratio | 1.56 | |||||
PB Ratio | 1.57 | |||||
Price-to-Tangible-Book | 1.57 | |||||
Price-to-Free-Cash-Flow | 4.56 | |||||
Price-to-Operating-Cash-Flow | 4.4 | |||||
EV-to-EBIT | 2.09 | |||||
EV-to-EBITDA | 2.02 | |||||
EV-to-Forward-EBITDA | -2.91 | |||||
EV-to-Revenue | 1.02 | |||||
EV-to-Forward-Revenue | 3.9 | |||||
EV-to-FCF | 3.58 | |||||
Price-to-Projected-FCF | 10.95 | |||||
Price-to-Graham-Number | 0.44 | |||||
Price-to-Net-Current-Asset-Value | 1.81 | |||||
Price-to-Net-Cash | 3.21 | |||||
Earnings Yield (Greenblatt) % | 47.85 | |||||
FCF Yield % | 16.29 |